The simultaneous use of these two anti-HER2 drugs is known as dual HER2 blockade, which synergistically inhibits the HER2 signaling pathway and enhances anti-tumor activity by blocking the formation of HER2 heterodimers. This evidence concerns the gene ERBB2 and neoplasm.